The Government has secured the supply of 60 million doses of a Covid-19 vaccine candidate being developed in France.
Valneva SE, a specialist vaccine company, announced a “major parternship” with the UK worth around £433 million. The doses will be provided in the second half of 2021.
There is an option for the Government to access a further 130 million doses between 2022 and 2025, the company said.
The vaccine candidate, VLA2001, is expected to enter clinical studies at the end of the year, with regulatory approval following any successful outcome in the second half of 2021.
The UK will also invest in Valneva’s manufacturing facility in Livingston, Scotland, to help scale up production of the vaccine.
Alok Sharma, the business secretary, said: “Having visited Valneva just last month, I have seen first-hand the incredible work they are doing to develop and manufacture a Covid-19 vaccine.
“This new agreement could help us vaccinate millions of people across the country, as well as help create a UK vaccine manufacturing facility to speed up access to a potential Covid-19 candidate and boost the country’s resilience against future pandemics.”